Device Trial Radar · NCT04395131
Clearum High Flux Hemodialyzer Used in Hemodialysis for Subjects With End-Stage Renal Disease
Last checked: Nov 19, 2026Latest source record: Apr 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
20
Actual
Start
Apr 3, 2020
Primary completion
Aug 14, 2020
Study completion Aug 14, 2020
Sponsor
- Lead sponsor
- Mozarc Medical US LLCNot on our public-company list
- Sponsor type
- Industry
- First posted
- May 20, 2020
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study will be a prospective, interventional, non-randomized, single-center study in 20 ESRD patients on hemodialysis. The study will compare performance of the Clearum HS dialyzer to typical values obtained with other commercially available high flux dialyzers. In addition, the Clearum HS dialyzer will be compared to a Fresenius FX80 dialyzer for a baseline (control) comparison. This will be a post-market study. The duration of the trial is 2 weeks for the FX80 control dialyzer + 6 weeks with the Clearum HS dialyzer used for 3x weekly high flux hemodialysis.
Conditions
- End-stage Renal Disease
Interventions
Clearum HF HemodialyzerDevice
the hemodialyzer will be used 3x week for 3.5-4.5 hours with a Qb of at least 350 ml/min
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluate performance of small-solute (toxin) removalTime frame: End of dialysis treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
DaVita Clinical Research Germany
Düsseldorf, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.